1CM (MILFF) Return-on-Tangible-Equity: 59.03% (As of Feb. 2026)


What is 1CM Return-on-Tangible-Equity?

1CM MILFF Return-on-Tangible-Equity is 59.03% as of Feb. 2026. The stock has 4 warning signs investors should review. Among 897 Drug Manufacturers companies, 1CM ranks better than 82.27% on this metric.

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. 1CM's annualized net income for the quarter that ended in Feb. 2026 was $11.48 Mil. 1CM's average shareholder tangible equity for the quarter that ended in Feb. 2026 was $19.46 Mil. Therefore, 1CM's annualized Return-on-Tangible-Equity for the quarter that ended in Feb. 2026 was 59.03%.

The historical rank and industry rank for 1CM's Return-on-Tangible-Equity or its related term are showing as below:

MILFF' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -1248.81   Med: -76.9   Max: 23.13
Current: 23.13

During the past 13 years, 1CM's highest Return-on-Tangible-Equity was 23.13%. The lowest was -1,248.81%. And the median was -76.90%.

MILFF's Return-on-Tangible-Equity is ranked better than
82.27% of 897 companies
in the Drug Manufacturers industry
Industry Median: 7.89 vs MILFF: 23.13

1CM  (OTCPK:MILFF) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


1CM Return-on-Tangible-Equity Related Terms


1CM Return-on-Tangible-Equity Historical Data

* Premium members only.

The historical data trend for 1CM's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

1CM Return-on-Tangible-Equity Chart

1CM Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -81.64 9.56 3.08

1CM Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.69 2.35 -5.26 9.10 59.03

MILFF vs ZTS, UTHR: Return-on-Tangible-Equity Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, 1CM's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


1CM Return-on-Tangible-Equity vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, 1CM's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where 1CM's Return-on-Tangible-Equity falls into.



1CM Return-on-Tangible-Equity Calculation

1CM's annualized Return-on-Tangible-Equity for the fiscal year that ended in Aug. 2025 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Aug. 2025 )  (A: Aug. 2024 )(A: Aug. 2025 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Aug. 2025 )  (A: Aug. 2024 )(A: Aug. 2025 )
=0.352/( (5.297+17.55 )/ 2 )
=0.352/11.4235
=3.08 %

1CM's annualized Return-on-Tangible-Equity for the quarter that ended in Feb. 2026 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Feb. 2026 )  (Q: Nov. 2025 )(Q: Feb. 2026 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Feb. 2026 )  (Q: Nov. 2025 )(Q: Feb. 2026 )
=11.484/( (17.79+21.122)/ 2 )
=11.484/19.456
=59.03 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Feb. 2026) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.

What does a Return-on-Tangible-Equity of 59.03% mean?
1CM (MILFF) has a Return-on-Tangible-Equity of 59.03% as of Feb. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on 1CM and its competitors. According to the industry distribution chart, 1CM ranks #159 out of 897 companies in the Drug Manufacturers industry, placing it in the top 17.7%.
Is 1CM's Return-on-Tangible-Equity too high?
1CM's current Return-on-Tangible-Equity is 59.03%. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.89. 1CM's value of 59.03% is 648.2% above this industry median. Based on the distribution chart, 1CM ranks #159 out of 897 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does 1CM's Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, 1CM ranks #159 out of 897 companies for Return-on-Tangible-Equity. This places 1CM in the top 18% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 7.89. 1CM's value of 59.03% is 648.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.89, based on 897 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 1CM's current Return-on-Tangible-Equity of 59.03% is 648.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on 1CM and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 1CM's current Return-on-Tangible-Equity is 59.03%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 1CM stock overvalued right now?
Based on GuruFocus' analysis, 1CM (MILFF) is currently considered Significantly Undervalued. The stock's GF Value™ is $0.27, compared to a current price of $0.08 — trading 71.1% below its estimated fair value. The current Return-on-Tangible-Equity is 59.03% and 648.2% above the Drug Manufacturers industry median of 7.89. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For 1CM (MILFF), the current Return-on-Tangible-Equity is 59.03% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

1CM Business Description

Other Exchanges EPIC:Canada
Address 625 Cochrane Drive, Suite 802, Markham, ON, CAN, L3R9R9
1CM Inc is a multi-jurisdictional cannabis company focused on its retail customers and technology to democratize cannabis markets. The Company focuses on expanding its current operations through organic growth and by way of merger and acquisition transactions. It has a single operating segment, being Cannabis.